Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016647 | 0.81 | MGAM (0.38) | NLRP3APLNR | |
| SCHEMBL31644764 | 0.79 | CHRNB2 (0.30) | — | |
| SCHEMBL3710509 | 0.78 | GAA (0.33) | — | |
| SCHEMBL15535983 | 0.75 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL15005911 | 0.75 | HPGD (0.34) | — | |
| SCHEMBL28133171 | 0.74 | APLNR (0.36) | NLRP3APLNR | |
| SCHEMBL3527283 | 0.73 | MGAM (0.48) | — | |
| SCHEMBL13097057 | 0.71 | APLNR (0.37) | NLRP3APLNR | |
| SCHEMBL1662722 | 0.71 | CHRNB2 (0.42) | — | |
| SCHEMBL31644448 | 0.71 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133989-A1 | SMYD MODULATORS AND USES THEREOF | ALT-BIO PTE. LTD. (SG) | 2025-06-26 | — | — | WO | disclosed |
| EP-3288942-B1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-10-27 | — | — | EP | disclosed |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-10 | — | — | US | disclosed |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-07-16 | — | — | US | disclosed |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-15 | — | — | US | disclosed |
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
| WO-2016174079-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | NLRP3 19/4885APLNR 4159/4885 |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | NLRP3 19/4885APLNR 4159/4885 |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | NLRP3 19/4885APLNR 4159/4885 |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | NLRP3 19/4885APLNR 4159/4885 |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | NLRP3 19/4885APLNR 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.